Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AbbVie

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?

AbbVie has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

MarketBeat

Tariffs Are About to Make Your Beauty Routine a Lot More Expensive

Here are the treatments that are most vulnerable to price hikes.

Marie Claire

From analysis to the latest developments in health,
read the most diverse news in one place.

If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.

MarketBeat

Earnings Preview: What to Expect From AbbVie's Report

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

Barchart

3 Biopharmaceutical Stocks Bucking the Sell-Off

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

MarketBeat

Did pharma sector dodge Trump’s tariffs? The EU's not so sure

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Euronews

Read news from The Economist, FT, and more,
with one subscription

AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

MarketBeat

3 Top Dividend Kings to Scoop Up for Passive Income

Dividend Kings are good choices for reliable, low-risk investing.

Barchart

These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

MarketBeat

Is Wall Street Bullish or Bearish on AbbVie Stock?

Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.

Barchart

These 3 Dividend Aristocrats Could Be Your Best Investments This Year

Trying to make sense of market uncertainty? These 3 Dividend Aristocrats offer stability, strong yields & growth potential to help you weather 2025’s volatility.

Barchart

Stocks Retreat in Afternoon Trading

This afternoon, the S&P 500 Index ($SPX ) (SPY ) is down -0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.71%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up -0.36%. Stocks are moving lower this afternoon, after the Dow Jones Industrials posted an...

Barchart

Stocks Climb on Solid Corporate Earnings Results

The S&P 500 Index ($SPX ) (SPY ) today is up +0.67%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.32%. March E-mini S&P futures (ESH25 ) are up by +0.71%, and March E-mini Nasdaq...

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.

Barchart

Stocks Climb on Apple Earnings Results and Benign US Inflation News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.85%. March E-mini S&P futures (ESH25 ) are up by +0.42%, and March E-mini Nasdaq...

Barchart

Stock Index Futures Climb as Apple and Intel Provide a Boost, U.S. PCE Inflation Data in Focus

March S&P 500 E-Mini futures (ESH25) are up +0.46%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.73% this morning as solid earnings from Apple and Intel buoyed sentiment, while investors geared up for the release of the Federal Reserve’s first-line inflation gauge.

Barchart

3 Recession-Proof Dividend Stocks To Buy Today

Companies with long track records of increasing dividends can be a sound way to generate income in retirement. There's three top companies to look at today.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

AbbVie's Quarterly Earnings Preview: What You Need to Know

Pharma giant AbbVie is gearing up to announce its fourth-quarter results later this month and analysts expect a double-digit drop in earnings.

Barchart

2 Dividend Stocks You Can’t Miss in 2025

These companies are well-established with a solid track record of earnings growth and can cushion your portfolio with stability.

Barchart

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

3 Highest-Yielding Dividend Kings To Buy Today

Start your New Year early by exploring high-yield Dividend Kings with decades of growth, top analyst ratings, and attractive yields for long-term investors.

Fortune

Parkinson's disease symptoms reduced by drug in late-stage trial

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose.

Benzinga

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 10 unusual trades.

Barchart

Is AbbVie Stock Underperforming the Dow?

AbbVie has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.